Radiation therapy is one of the most effective cancer treatments available, used in roughly half of all cancer cases at some point during treatment. Its effectiveness varies significantly by cancer type, stage, and whether it’s used alone or alongside surgery and chemotherapy, but cure rates for certain early-stage cancers exceed 95%. Even when a cure isn’t the goal, radiation relieves pain from bone metastases in more than 80% of patients.
How Radiation Kills Cancer Cells
Radiation works by damaging the DNA inside cancer cells so severely that they can no longer divide and grow. This happens through two pathways. The first is direct: high-energy beams strip electrons from DNA molecules, breaking the strands apart. The second is indirect and actually accounts for most of the damage. When radiation hits the water molecules surrounding DNA, it triggers a chain reaction that produces highly reactive molecules called free radicals, along with hydrogen peroxide and other oxidizers. These chemical byproducts are short-lived (lasting roughly a trillionth of a second) but potent enough to shred nearby DNA as they spread outward from the initial impact site.
Cells have built-in repair systems that can fix some of this damage. Healthy cells tend to repair themselves more efficiently than cancer cells, which is why radiation can be targeted to kill tumors while sparing most surrounding tissue. When cancer cells fail to repair the damage, they either die outright or trigger their own self-destruct sequence, a process called programmed cell death. This doesn’t happen instantly. It takes days or weeks of treatment before enough DNA damage accumulates to start killing cancer cells, and those cells continue dying for weeks or even months after treatment ends.
Effectiveness in Early-Stage Cancers
Radiation’s track record is strongest in localized cancers that haven’t spread to distant sites. The numbers vary by cancer type, but several common cancers respond remarkably well.
For early breast cancer, adding radiation after lumpectomy cuts the absolute risk of the cancer coming back within 10 years from 35% to 19%, a 16-percentage-point drop. In relative terms, that’s nearly a 50% reduction in recurrence risk over the first decade. This survival benefit is why radiation after breast-conserving surgery became standard practice.
Prostate cancer shows similarly strong results. In a study comparing two forms of external radiation for intermediate-risk prostate cancer, more than 95% of patients remained free of any signs the cancer had returned five years after treatment. Specifically, the biochemical failure-free rate was 95.7% for patients who received a newer, shorter course of treatment and 94.6% for those on a conventional schedule.
For early-stage lung cancer, stereotactic body radiation therapy (a highly focused form of radiation delivered in fewer sessions) has shown statistically significant improvements in both local tumor control and overall survival compared with older conventional approaches, based on a major phase III clinical trial.
Shorter Treatment Schedules Work Just as Well
One of the biggest shifts in radiation therapy over the past decade is the move toward fewer, higher-dose treatment sessions. Traditional radiation for prostate cancer, for example, involved daily treatments five days a week for seven to nine weeks. Current clinical guidelines now recommend shorter schedules as the standard option across all risk levels.
Moderate hypofractionation (delivering a slightly larger dose per session over about four to six weeks instead of seven to nine) carries a “strong recommendation” backed by high-quality evidence for low, intermediate, and high-risk prostate cancer. This applies regardless of patient age, other health conditions, or anatomy. Ultrahypofractionation goes even further, compressing the entire treatment course into as few as five sessions. This approach is currently recommended for low and intermediate-risk cases.
The practical difference for patients is significant. Instead of 40 or more trips to a treatment center, some patients now complete radiation in a single week with equivalent cancer control. Similar trends toward shorter schedules are happening across breast, lung, and other cancers.
Radiation for Pain Relief
When cancer spreads to the bones, radiation is one of the most reliable ways to control the pain. In a prospective study tracking patients with painful bone metastases, 86% experienced meaningful pain relief after radiation. Across the broader medical literature, the response rate ranges from 50% to 80%, with up to one-third of patients achieving complete pain relief at the treated site. This palliative use of radiation is typically delivered in just one to ten sessions and can dramatically improve quality of life even when the underlying cancer is advanced.
Side Effects and Long-Term Risks
Radiation’s effectiveness comes with trade-offs. Short-term side effects depend on which part of the body is being treated and typically include fatigue, skin irritation in the treatment area, and inflammation of nearby tissues. These usually resolve within weeks after treatment ends.
The more serious concern is long-term risk. Because radiation damages DNA, it can occasionally cause new cancers years or decades later. The risk varies considerably by situation. Among women who received breast radiation, 13% eventually developed a second cancer, though only about 3.4% of those cases were directly attributable to the radiation itself. For men treated for prostate cancer, those who received radiation had a 1.2% higher incidence of a second primary cancer compared with men treated without radiation. Children face the highest relative risk: in one U.S. study, 8.3% of children who received radiation for a primary tumor went on to develop a secondary cancer.
These numbers need context. For most adults with cancer, the benefit of treating the existing tumor far outweighs the small added risk of a future second cancer. But the calculus is more nuanced for children and young adults, who have decades of life ahead in which a radiation-induced cancer could develop. This is one reason oncologists are increasingly precise about targeting radiation and reducing the dose to surrounding healthy tissue.
Why Results Vary Between Patients
Several factors influence how well radiation works for any individual. Tumor size and stage matter most: small, localized tumors respond far better than large or metastatic ones. The type of cancer also plays a role. Some cancers, like lymphomas and certain head and neck cancers, are highly radiosensitive, meaning their cells are especially vulnerable to DNA damage. Others, like melanoma and certain sarcomas, are more resistant.
Oxygen levels within the tumor affect outcomes too. Cells surrounded by oxygen-rich blood produce more of those destructive free radicals during radiation, amplifying the damage. Tumors with poor blood supply and low oxygen levels tend to resist radiation more effectively. This is partly why radiation is often combined with other treatments. Surgery can remove the bulk of a tumor, and chemotherapy can sensitize remaining cells, making radiation more effective against whatever is left.
The timeline for seeing results also varies. Cancer cells continue dying for weeks to months after the last radiation session, so imaging scans done immediately after treatment may not show the full response. Most oncologists schedule follow-up scans several weeks to a few months after treatment ends to assess how much the tumor has shrunk.